Clinical trials: Thromboembolus
Venous Thromboembolism
High-Risk Factors for VTE Death
Study population and characteristics This retrospective cohort study initially screened 105,168 consecutive hospitalized patients at Shihezi People's Hospital from February 2022 to June 2025.
- Trial name
- NCT07767279
- Testing
- comorbidity, Respiratory Failure, Sepsis
- Where
- China
- Volunteers
- 105,168 people
- Sponsor
- China International Neuroscience Institution
Myotonic Dystrophy 1
Venous Thromboembolism in Myotonic Dystrophy Type 1
Investigators identified a high risk of deep vein thrombosis and pulmonary embolism in patients presenting myotonic dystrophy type 1 treated in our hospital, 10 times higher than general population matched on age and sex.
- Trial name
- DM1-VTE (NCT03424460)
- Testing
- Haemostasis tests, Monocytes and megacaryocytes culture and RNA extraction, RNA extraction
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism
the Effectiveness of Different Risk Scales In Predicting VTE in Respiratory Inpatients
To compare the predictive effectiveness of the Caprini risk assessment model, the Padua risk assessment model and the VTE risk assessment in medical patients mentioned in the 2018 edition of the Guidelines for the diagnosis…
- Trial name
- NCT04963374
- Testing
- risk evolution scale
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Venous Thromboembolism, Pulmonary Embolism
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening.
- Trial name
- PHACS (NCT00876915)
- Testing
- dalteparin injection
- Where
- 7 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- University of Rochester
Venous Thromboembolism, Anticoagulant
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal…
- Conditions
- Venous Thromboembolism, Anticoagulant, Elderly
- Trial name
- Jason (NCT04257487)
- Testing
- Sulodexide
- Where
- Italy
- Volunteers
- 1,455 people
- Sponsor
- Arianna Anticoagulazione Foundation
Prostate Cancer, Thromboembolism
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014352
- Testing
- docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cerebral Venous Thrombosis
Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis
This study aims to evaluate the efficacy and safety of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, combined with standard anticoagulant therapy compared with standard anticoagulant therapy alone in patients with…
- Trial name
- NCT07801638
- Testing
- Tocilizumab, Standard Treatment
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Capital Medical University
Atrial Fibrillation, Venous Thromboses
Pharmacogenetic Dosage Algorithm for Acenocoumarol
The use of coumarins has been a challenge for doctors because of its narrow therapeutic range and they show great inter and intra-individual variability in the dose necessary to achieve an international normalized ratio (INR)…
- Conditions
- Atrial Fibrillation, Venous Thromboses, Cardiac Valve Disease
- Trial name
- NCT03015025
- Testing
- Acenocoumarol
- Where
- Spain
- Volunteers
- 340 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Deep Vein Thrombosis, Pulmonary Embolism
D-Dimer and IPG for Recurrent Thrombosis (DIRECT)
To simplify and improve the diagnostic approach to patients with clinically suspected recurrent DVT by determining whether the results of the combination of IPG and d-dimer testing, using a whole blood agglutination assay, can be…
- Trial name
- NCT00182247
- Testing
- venogram
- Where
- 8 sites in Canada, Italy
- Volunteers
- 600 people
- Sponsor
- Hamilton Health Sciences Corporation
Pulmonary Embolus/Emboli, Thromboembolism, Pulmonary
Venous Phase Dual Energy CT in Patients Suspected for Pulmonary Embolism.
Venous phase spectral or dual energy (DE) chest computed tomography (CT) in patients with suspected pulmonary embolism (PE) compared to standard computed tomography pulmonary angiography (CTPA): sensitivity, evaluation of iodine…
- Trial name
- NCT04859478
- Testing
- Dual energy / spectral portal venous chest computed tomography
- Where
- 2 sites in Denmark
- Volunteers
- 160 people
- Sponsor
- Copenhagen University Hospital at Herlev
Venous Thromboembolism, Delivery of Health Care
Improving Venous Thromboembolism Prophylaxis
Preventing the formation of blood clots in the veins so they do not injure leg veins or travel to the lungs, also called venous thromboembolism prophylaxis (VTE-P) is an essential component of safe in-patient care, yet it is…
- Conditions
- Venous Thromboembolism, Delivery of Health Care, Quality Improvement
- Trial name
- NCT01304108
- Testing
- VTE-P Tollgate, BLAZE Pop up, Usual Care
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada.
- Trial name
- COBRRA (NCT03266783)
- Testing
- Apixaban, Rivaroxaban
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 2,760 people
- Sponsor
- Ottawa Hospital Research Institute
Non-Small Cell Lung Carcinoma, Venous Thromboembolism
Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma
The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis.
- Trial name
- NCT00192829
- Testing
- Blood sample withdrawal
- Where
- 2 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Rambam Health Care Campus
Thromboembolism
Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
CV185118 is a single dose Apixaban PK/PD study in pediatric participants. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric participants at risk for thrombosis
- Trial name
- NCT01707394
- Testing
- Apixaban
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
A study for subjects with atrial fibrillation (AF) or atrial flutter who are diagnosed with left atrial (LA) or left atrial appendage (LAA) thrombus. The study will assign subjects to rivaroxaban for treatment of thrombi.
- Trial name
- X-TRA (NCT01839357)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 31 sites in Bulgaria, France and 5 more
- Volunteers
- 60 people
- Sponsor
- Bayer
Atrial Fibrillation, Tachycardia
Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems
This is an observational registry study aiming to collect data on efficacy and safety of the single chamber Biotronik DX system with enhanced atrial diagnostics. The minimal follow-up period is 24 months.
- Conditions
- Atrial Fibrillation, Tachycardia, ICD Therapy, Thromboembolic Events
- Trial name
- MATRIX (NCT01774357)
- Where
- Germany
- Volunteers
- 2,054 people
- Sponsor
- Biotronik SE & Co. KG
Acute Exacerbation Copd, Venous Thromboembolism
Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD
AECOPD increases the risk of VTE.VTE prevention is a long way to go for high-risk VTE patients in China.The incidence of AECOPD complicated with VTE in Asian population is high and the mortality rate is high.Rivaroxaban, a new…
- Trial name
- SUPREME (NCT03277001)
- Testing
- Rivaroxaban, Enoxaparin
- Where
- China
- Volunteers
- 438 people
- Sponsor
- Huashan Hospital
Cerebral Venous Thrombosis
Evaluation of Cerebral Oxygenation and Hemodynamics in Patients With Cerebral Venous Thrombosis
Cerebral hypoperfusion and hypoxia are the major determinants of neurological outcomes following acute brain injury as proved in Traumatic Brain Injury/Sub Arachnoid Haemhorrhage literature.
- Trial name
- NCT03033966
- Testing
- NIRS based Cerebral Oximetry
- Where
- India
- Volunteers
- 17 people
- Sponsor
- Dhritiman Chakrabarti
Venous Thromboembolism
Safety and Efficacy Study of Fitaya Vena Cava Filter
A Multi-center, Randomized Controlled Trial to evaluate the safety and efficacy of Fitaya Vena Cava Filter manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for deep vein thrombosis.
- Trial name
- NCT03691753
- Testing
- Fitaya Vena Cava Filter System, Aegisy Vena Cava Filter
- Where
- 13 sites in China
- Volunteers
- 186 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Aging
Effect of Aging on Haemostasis Parameters
Aging is an independent risk factor, without any clear explanation. The primary aim of the study is to depict the effect of aging on the coagulation fibrinolysis parameters and microparticles.
- Trial name
- NCT00299624
- Where
- 2 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hopital Lariboisière